



UNITED STATES PATENT AND TRADEMARK OFFICE

10
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/664,603	09/17/2003	Guy A. Rouleau	GOUD:023USDI	3929
7590	06/20/2006		EXAMINER	LIU, SUE XU
Michael R. Krawzsenek Fulbright & Jaworski L.L.P. 600 Congress Avenue, Suite 2400 Austin, TX 78701			ART UNIT	PAPER NUMBER
			1639	

DATE MAILED: 06/20/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	10/664,603	ROULEAU ET AL.
	Examiner	Art Unit
	Sue Liu	1639

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on ____.
 2a) This action is **FINAL**. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 14-33 is/are pending in the application.
 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
 5) Claim(s) ____ is/are allowed.
 6) Claim(s) ____ is/are rejected.
 7) Claim(s) ____ is/are objected to.
 8) Claim(s) 14-33 are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on ____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. ____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date: ____.
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date: ____.	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
	6) <input type="checkbox"/> Other: ____.

DETAILED ACTION

Claim Status

Claims 1-13 have been canceled as filed on 9/17/03;

Claims 14-33 are currently pending.

Election/Restrictions

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 14-28, drawn to an assay for selecting a compound that effects a sodium channel, classified variously, for example in class 536, subclass 23.1.
 - II. Claims 29-33, drawn to a method of identifying a compound for treating epilepsy or other neurological disorders, classified variously, for example in class 424, subclass 94.1.

Further Restriction (Note: This is not species selection.)

The inventions listed as Group I are subjected to further restrictions as set forth below:

- a. Applicants are further requested to select a single specific DNA sequence identified by its corresponding SEQ ID NO.
- b. Applicants are further requested to select a single specific amino acid sequence identified by its corresponding SEQ ID NO.

The “Further Restrictions” are deemed proper since each one of the restrictions would

result in an amino acid sequence or a nucleic acid sequence that possesses distinct function and/or structures. The different proteins would not share the same core structure, and would also have different properties (such as 3-D folding structures and target binding properties) and therefore different functions. Thus, these different peptides or nucleic acids would have different modes of operation, different effects, and can be used in different methods. In addition, a search of multiple sequences would impose undue search burden on the office.

The inventions are distinct, each from the other because of the following reasons:

2. Inventions of Groups I and II are directed to related processes. The related inventions are distinct if the inventions as claimed do not overlap in scope, i.e., are mutually exclusive; the inventions as claimed are not obvious variants; and the inventions as claimed are either not capable of use together or can have a materially different design, mode of operation, function, or effect. See MPEP § 806.05(j). In the instant case the different inventions in Groups I and II are directed to various distinct methods, because they use different steps, require different reagents and/or will produce different results. The invention of Group II directs to a method of identifying a compound having therapeutic effects, and requires the steps and/or reagents of “providing a screening assay which comprises a measurable SCN3A biological activity”, and the identified compound having therapeutic effects for specific diseases such as epilepsy, which are steps and/or reagents that are not required by Group I method. Group I method only requires the step of screening for a test compound that effects a sodium channel. Art anticipating or rendering obvious each of the above identified groups respectively would not necessarily anticipate or render obvious another group, because they are drawn to different inventions that have different

distinguishing features and/or characteristics. Consequently, Groups I and II have different issues regarding patentability and enablement and represent patentably distinct subject matter. Thus, inventions of Groups I and II are distinct, and restriction between the groups is proper.

3. Therefore, these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and/or recognized divergent subject matter. Even though some of the groups are classified in the same class/subclass, this has no effect on the non-patent literature search. The different methods and products will require completely different searches in both the patent and non-patent databases, and there is no expectation that the searches will be coextensive. Therefore, these do create an undue search burden, and restriction for examination purposes as indicated is proper.

Species Election

4. This application contains claims directed to the following patentably distinct species of the claimed invention. Applicants are requested to further elect **a single ultimate species for each** of the following:

- A.) A single specific disorder.
- B.) A single specific species of a compound (or an agent).
- C.) A single specific selection of inactivation OR activation of the sodium channel.
- D.) A single specific mammalian species from which the sodium channel sequence is derived.
- E.) A single specific selection of a cell-free system OR a whole cell system.

The species are distinct, each from the other, because their structure and modes of action are different. They would also differ in their reactivity and the starting materials from which they are made. For different species of method, the method steps for each species would differ. Moreover, the above species can be separately classified. Consequently, the species have different issues regarding patentability and represent patentably distinct subject matter. Therefore, this does create an undue search burden, and election for examination purpose as indicated is proper.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, Claims 14-33 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

5. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

6. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).


Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sue Liu whose telephone number is 571-272-5539. The examiner can normally be reached on M-F 9am-3pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Peter Paras can be reached on 571-272-4517. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

SL
Art Unit 1639
6/9/06



MARK SHIBUYA, PH.D.
PATENT EXAMINER